<DOC>
	<DOCNO>NCT01899703</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study ass safety tolerability GSK2330672 administration subject primary biliary cirrhosis ( PBC ) symptoms pruritus . It double-blind , crossover study subject receive placebo GSK23306772 random order two 14-day treatment period . Additionally , study determine GSK2330672 exposure interaction ursodeoxycholic acid ( UDCA ) . The total duration subject participation 14 week screen ( 45 day ) treatment period . Subjects eligible enrolment participate 2-week placebo run-in period . Subjects randomize crossover fashion ( Sequence 1 / Sequence 2 ) receive placebo GSK2330672 treatment two consecutive 2-week study period . Subjects participate 2-week placebo dose period end follow-up assessment . Study result utilized form benefit : risk profile GSK2330672 PBC determine plan progression exploratory efficacy trial</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Repeat Doses GSK2330672 Administration Subjects With Primary Biliary Cirrhosis ( PBC ) Symptoms Pruritus</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Pruritus</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Cholestasis , Intrahepatic</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Male female age 18 75 year age inclusive , time signing informed consent . Proven likely PBC , demonstrate subject present least 2 follow : history sustain increased alkaline phosphatise ( AP ) level first recognize least 6 month prior Day 1 ; positive antimitochondrial antibody ( AMA ) titer ( &gt; 1:40 titer immunofluorescence M2 positive enzymelinked immunosorbent assay [ ELISA ] ) PBCspecific antinuclear antibody ( antinuclear dot nuclear rim positive ) ; liver biopsy consistent PBC . Screening AP value &lt; =10 Ã— upper limit normal ( ULN ) . Subjects stable dos UDCA &gt; 8 week time screen . Subjects take UDCA due intolerance may enrol study follow agreement GSK medical monitor . Symptoms pruritus follow ( one follow ) : PBC subject severe symptom pruritus significantly impact daily life proven refractory least one previous therapy discontinue due inadequate clinical response , poor tolerability adverse event . Temporary response cooling , 1 % menthol aqueous cream , nasobiliary drainage molecular adsorbent recirculating system ( MARS ) therapy still compatible refractory itch ; PBC subject unresolved symptom use single antipruritic agent tolerate washout current therapy duration trial ; PBC subject seek treatment pruritus newly diagnose previously untreated . A female subject eligible participate pregnant , confirm negative serum human chorionic gonadotrophin ( hCG ) test least one follow condition applies : Nonreproductive potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per milliliter estradiol &lt; 40 picograms per milliliter ( &lt; 147 picomole per liter ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method along either second form highly effective contraception barrier protection ( condom spermicide ) wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment ; Reproductive potential agree follow one contraception option method specify duration time . Capable give write informed consent , include compliance requirement restriction list consent form Screening total bilirubin &gt; 1.5x ULN . Isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % . Screening alanine aminotransferase aspartate aminotransferase &gt; 4x ULN . Screening serum creatinine &gt; 2.5 milligram per decilitre ( 221 micromole/liter ) . History presence hepatic decompensation ( e.g. , variceal bleeds , encephalopathy , poorly control ascites ) . History presence concomitant liver diseases include hepatitis due hepatitis B C virus ( HCV , HBV ) infection , primary sclerosing cholangitis ( PSC ) , alcoholic liver disease , definite autoimmune hepatitis biopsy proven nonalcoholic steatohepatitis ( NASH ) . Administration follow drug time 3 month prior screen study : colchicine , methotrexate , azathioprine , systemic corticosteroid . Current chronic history inflammatory bowel disease , chronic diarrhea , Crohn 's disease diarrhea relate malabsorption syndrome . Fecal occult blood positive test screening . Based average correct QT interval ( QTc ) value triplicate ECGs obtain least 5 minute apart : QTc &gt; =450 millisecond ( msec ) ; QTc &gt; =480 msec subject Bundle Branch Block . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( approximately 240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit A positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine Where participation study would result donation blood blood product excess 500 mL within 56 day period . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Intestinal bile acid transport inhibitor</keyword>
	<keyword>Pruritus</keyword>
	<keyword>Primary biliary cirrhosis</keyword>
	<keyword>Ursodeoxycholic acid</keyword>
	<keyword>GSK2330672</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>